Skip to content
Oxbryta(voxelotor)
Oxbryta (voxelotor) is a small molecule pharmaceutical. Voxelotor was first approved as Oxbryta on 2019-11-25. It is used to treat sickle cell anemia in the USA. It has been approved in Europe to treat anemia, hemolytic anemia, and sickle cell anemia. It is known to target cytochrome P450 2C8, cytochrome P450 3A4, and cytochrome P450 2C9.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
Oxbryta
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Voxelotor
Tradename
Company
Number
Date
Products
OXBRYTAGlobal Blood TherapeuticsN-213137 RX2019-11-25
2 products, RLD, RS
OXBRYTAGlobal Blood TherapeuticsN-216157 RX2021-12-17
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
oxbrytaNew Drug Application2021-01-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
sickle cell anemiaEFO_0000697D000755D57
Agency Specific
FDA
EMA
Expiration
Code
VOXELOTOR, OXBRYTA, GLOBAL BLOOD THERAPS
2028-12-17ODE-394
2026-11-25ODE-281
2024-11-25NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Voxelotor, Oxbryta, Global Blood Theraps
104930352037-10-12DP
110203822036-12-02U-3133, U-3134
94470712035-02-06DS, DP
107225022035-02-06DP
114527202035-02-06U-3459
92481992034-01-29U-2676, U-2715
90182102033-11-25DS, DP
100174912032-12-28DP
100348792032-12-28DS, DP
108067332032-12-28DP
ATC Codes
B: Blood and blood forming organ drugs
— B06: Other hematological agents in atc
— B06A: Other hematological agents in atc
— B06AX: Other hematological agents in atc
— B06AX03: Voxelotor
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sickle cell anemiaD000755EFO_0000697D575663423
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Leg ulcerD007871——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoxiaD000860R09.02—2———2
Idiopathic pulmonary fibrosisD054990J84.112—2———2
Acute lung injuryD055371EFO_0004610—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N191————1
Hepatic insufficiencyD0485501————1
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVOXELOTOR
INNvoxelotor
Description
Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Voxelotor is the first hemoglobin oxygen-affinity modulator. Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. It has a safe profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity. It was developed by Global Blood Therapeutics, a subsidiary of Pfizer.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O
Identifiers
PDB—
CAS-ID1446321-46-5
RxCUI—
ChEMBL IDCHEMBL4101807
ChEBI ID—
PubChem CID71602803
DrugBankDB14975
UNII ID3ZO554A4Q8 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CYP2C8
CYP2C8
CYP3A4
CYP3A4
CYP2C9
CYP2C9
Organism
Homo sapiens
Gene name
CYP2C8
Gene synonyms
NCBI Gene ID
1558
Protein name
cytochrome P450 2C8
Protein synonyms
CYPIIC8, Cytochrome P450 form 1, Cytochrome P450 IIC2, Cytochrome P450 MP-12, Cytochrome P450 MP-20, cytochrome P450, family 2, subfamily C, polypeptide 8, cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8, flavoprotein-linked monooxygenase, microsomal monooxygenase, P450 form 1, S-mephenytoin 4-hydroxylase, xenobiotic monooxygenase
Uniprot ID
Q9UCZ9
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Oxbryta - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 406 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
661 adverse events reported
View more details